Table 2.
Unadjusted hazard ratios for death or new heart failure
| Unadjusted HR | 95% Confidence Interval | P value | |
|---|---|---|---|
| ANTHROPOMETRIC | |||
| Age (75 y) |
1.70 |
0.92 – 3.17 |
0.093 |
| Male sex |
0.92 |
0.67 – 1.27 |
0.614 |
| Body mass index >30 |
1.04 |
0.49 – 2.20 |
0.916 |
| RISK FACTORS | |||
| Familiar history of CAD |
1.16 |
0.68 – 1.96 |
0.588 |
| Smoking habit |
2.22 |
1.23 – 4.00 |
0.008 |
| Diabetes |
0.88 |
0.45 – 1.70 |
0.698 |
| Hypertension |
1.00 |
0.59 – 1.70 |
0.999 |
| Hypercholesterolemia |
1.13 |
0.66 – 1.92 |
0.664 |
| # risk factors ≥ 3 |
1.58 |
0.93 – 2.69 |
0.093 |
| CLINIC | |||
| Previous CAD diagnosis |
8.76 |
1.21 – 63.3 |
0.032 |
| Previous myocardial infarction |
2.51 |
1.32 – 4.76 |
0.005 |
| NYHA classification ≥ 3 |
5.81 |
2.99 – 11.3 |
<0.0001 |
| Revascularization in the follow-up |
0.36 |
0.15 – 0.85 |
0.019 |
| THERAPY | |||
| β-blockers |
1.00 |
0.55 – 1.81 |
0.997 |
| Ca++−antagonist |
1.15 |
0.63 – 2.12 |
0.644 |
| Nitrates |
0.92 |
0.54 – 1.56 |
0.753 |
| Loop diuretics |
5.26 |
2.94 – 9.40 |
<0.0001 |
| Aldosterone antagonist |
5.69 |
3.29 – 9.86 |
<0.0001 |
| ACE-inhibitors/AT1-receptors antagonist |
1.45 |
0.71 – 2.96 |
0.310 |
| ASA |
0.69 |
0.36 – 1.30 |
0.251 |
| Statins |
0.94 |
0.53 – 1.68 |
0.837 |
| Anticoagulant |
6.38 |
3.49 – 11.7 |
<0.0001 |
| ECG | |||
| Heart rate (≥75 bpm) |
2.80 |
1.62 – 4.84 |
<0.001 |
| Non sinusal rhythm |
4.19 |
1.67 – 10.54 |
0.002 |
| QRS duration |
2.62 |
1.47 – 4.70 |
0.001 |
| QTc interval |
4.34 |
2.53 – 7.46 |
<0.0001 |
| LV hypertrophy |
1.00 |
0.47 – 2.11 |
0.995 |
| LBB block |
1.63 |
1.07 – 2.48 |
0.024 |
| RBB block |
1.30 |
0.62 – 2.76 |
0.489 |
| ST segment depression |
1.60 |
0.73 – 3.54 |
0.245 |
| Negative T waves |
1.76 |
1.03 – 3.00 |
0.039 |
| Q waves |
1.55 |
0.92 – 2.62 |
0.102 |
| ECHOCARDIOGRAPHY | |||
| LV EDV (≥ 105 ml/m2) |
4.66 |
2.34 – 9.29 |
<0.0001 |
| LV ESV (≥ 75 ml/m2) |
8.95 |
4.55 – 17.60 |
<0.0001 |
| LV EF (≤ 30%) |
12.34 |
6.80 – 22.38 |
<0.0001 |
| LV WMSI (≥ 2.32) |
10.94 |
5.53 – 21.62 |
<0.0001 |
| LV mass (≥ 310 g) |
4.89 |
2.05 – 11.70 |
<0.001 |
| LV diastolic function (≥ pseudo-normal)† |
7.03 |
4.00 – 12.38 |
<0.0001 |
| Mitral regurgitation (≥ moderate)‡ |
4.67 |
2.68 – 8.13 |
<0.0001 |
| Pulmonary hypertension |
4.86 |
2.68 – 8.80 |
<0.0001 |
| RVIT dilatation |
1.45 |
0.92 – 2.30 |
0.112 |
| RV dysfunction |
5.17 |
2.48 – 10.80 |
<0.0001 |
| CMR | |||
| LGE total burden ≥ 45% § |
13.61 |
7.32 – 25.31 |
<0.0001 |
| LGE total burden ≥ 20% # |
6.62 |
3.86 – 11.38 |
<0.0001 |
| LGE spatial Extent ≥ 68% § |
9.27 |
4.86 – 17.66 |
<0.0001 |
| LGE spatial Extent ≥16% # |
4.96 |
2.60 – 9.45 |
<0.0001 |
| LGE transmurality | 4.82 | 2.81 – 8.31 | <0.0001 |
LV = left ventricle; LVEF = left ventricle ejection fraction; LBB = left bundle branch; RBB = right bundle branch; MR = mitral regurgitation; RVIT = right ventricle inflow tract; LGE = late gadolinium enhancement.
† based on trans-mitral diastolic flow and pulmonary vein flow evaluation.
‡ based on effective regurgitate orifice area.
§ cut-off equal to the 95% percentile of the entire population.
# cut-off equal to the 75% percentile of the entire population.